PumpPepsLab/Lab nominalApr 30, 2026 · 20:05 UTCDEV / local

Active run

completed
msn_0013994f54644073

GLP-1 analogs with extended half-life

Completed · all 10 stages
Pipeline progress100%
Wall time3m 17s
Depthstandard
Spent / budget$0.00 / $8
Active agents0
Prediction commit · sha-256revealed
8b690bf75d0982d7001e93f55a91622a25614e7655b8195d5ff76602f66a0b7a
salt: 3bed8c38883bcc10fa0b76a84f776e6a

Swarm graph

0 active · 13 total
  • Orchestrator0/1
  • Literature Miner1/1
  • Sequence & Structure1/1
  • Target & Pathway1/1
  • Variant Linker1/1
  • ADMET Developability1/1
  • Novelty Scout1/1
  • Patent Competitive1/1
  • Thesis Generator1/1
  • Evidence Grader1/1
  • Red Team1/1
  • Synthesizer1/1
  • Dossier Assembler1/1

Research pipeline

5-layer DAG · 10 stages
01100%
Ingest4 tasks
02100%
Annotate1 cards
03100%
Novelty2 signals
04100%
Grade1 graded
05100%
Thesis1 drafts
06100%
Red Team1 critiques
07100%
Synthesize1 docs
08100%
Draft1 dossiers
09100%
QA Gate19 A/B theses
10100%
Deliver1 delivered

Evidence

coverage 100%
Findings across all missions31
Grade A evidence13
Theses produced1
Red-team critiques3
Source mix
PubMed
39%
Novelty
39%
ChEMBL
13%
Patent
10%
Confidence distribution
Low
0%
Med
39%
High
19%
Very High
42%

Data sources

live ingestion
  • PubMed12 cited
  • UniProtlive
  • AlphaFoldlive
  • OpenTargetslive
  • ChEMBLlive
  • Reactomelive

Findings feed

30 latest
  • Anovelty:pubmed:40499315
    open ↗
    Novelty signal · Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide.

    Whitespace score 1.00 — pubmed:40499315 previously seen in 0 mission(s).

  • Anovelty:pubmed:29949126
    open ↗
    Novelty signal · Clinical pharmacology of glucagon-like peptide-1 receptor agonists.

    Whitespace score 1.00 — pubmed:29949126 previously seen in 0 mission(s).

  • Anovelty:pubmed:39025754
    open ↗
    Novelty signal · GLP-1R agonist therapy and vaccine response: Neglected implications.

    Whitespace score 1.00 — pubmed:39025754 previously seen in 0 mission(s).

  • Anovelty:pubmed:39656031
    open ↗
    Novelty signal · The role of glucagon-like peptides in osteosarcopenia.

    Whitespace score 1.00 — pubmed:39656031 previously seen in 0 mission(s).

  • Anovelty:pubmed:38531211
    open ↗
    Novelty signal · Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

    Whitespace score 1.00 — pubmed:38531211 previously seen in 0 mission(s).

  • Anovelty:pubmed:33421947
    open ↗
    Novelty signal · A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis.

    Whitespace score 1.00 — pubmed:33421947 previously seen in 0 mission(s).

  • Anovelty:pubmed:29915923
    open ↗
    Novelty signal · Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.

    Whitespace score 1.00 — pubmed:29915923 previously seen in 0 mission(s).

  • Anovelty:pubmed:36356832
    open ↗
    Novelty signal · BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.

    Whitespace score 1.00 — pubmed:36356832 previously seen in 0 mission(s).

  • Anovelty:pubmed:33969456
    open ↗
    Novelty signal · Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.

    Whitespace score 1.00 — pubmed:33969456 previously seen in 0 mission(s).

  • Anovelty:pubmed:30009885
    open ↗
    Novelty signal · Battle of GLP-1 delivery technologies.

    Whitespace score 1.00 — pubmed:30009885 previously seen in 0 mission(s).

  • Anovelty:pubmed:31031702
    open ↗
    Novelty signal · The Discovery and Development of Liraglutide and Semaglutide.

    Whitespace score 1.00 — pubmed:31031702 previously seen in 0 mission(s).

  • Bpatent:general
    Patent landscape · general

    Estimated patent density: Whitespace FTO risk: Low Known ligands (ChEMBL): 0 Recent literature signal: 12 cited PubMed item(s)

  • Bpatent:Pro-glucagon
    Patent landscape · Pro-glucagon

    Estimated patent density: Whitespace FTO risk: Low Known ligands (ChEMBL): 136 Recent literature signal: 0 cited PubMed item(s)

  • Anovelty:pubmed:27633186
    open ↗
    Novelty signal · Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

    Whitespace score 1.00 — pubmed:27633186 previously seen in 0 mission(s).

  • Bpatent:Glucagon-like peptide 1 receptor
    Patent landscape · Glucagon-like peptide 1 receptor

    Estimated patent density: Crowded FTO risk: Elevated Known ligands (ChEMBL): 113,844 Recent literature signal: 0 cited PubMed item(s)

  • Bchembl:CHEMBL5736
    open ↗
    Pro-glucagon (SINGLE PROTEIN)

    Organism: Homo sapiens Known bioactivities: 136 Moderately interrogated; useful baseline.

  • Bchembl:CHEMBL5862
    open ↗
    Glucagon-like peptide 1 receptor (SINGLE PROTEIN)

    Organism: Rattus norvegicus Known bioactivities: 332 Moderately interrogated; useful baseline.

  • Cchembl:CHEMBL1075290
    open ↗
    Glucagon-like peptide 1 receptor (SINGLE PROTEIN)

    Organism: Mus musculus Known bioactivities: 62 Sparsely interrogated; potential whitespace.

  • Bchembl:CHEMBL1784
    open ↗
    Glucagon-like peptide 1 receptor (SINGLE PROTEIN)

    Organism: Homo sapiens Known bioactivities: 113,450 Heavily interrogated chemically; rich SAR baseline available.

  • Cpubmed:40499315
    open ↗
    Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide.

    The increasing prevalence of type 2 diabetes presents a major global health challenge. Glucagon-like peptide-1 (GLP-1) receptor agonists offer glycemic control, weight loss, and cardiovascular benefits but are limited by…

  • Cpubmed:29949126
    open ↗
    Clinical pharmacology of glucagon-like peptide-1 receptor agonists.

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type…

  • Cpubmed:39025754
    open ↗
    GLP-1R agonist therapy and vaccine response: Neglected implications.

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (Ozempic®), have emerged as effective treatments for diabetes and weight management. However, recent evidence indicates that GLP-1R signallin…

  • Cpubmed:39656031
    open ↗
    The role of glucagon-like peptides in osteosarcopenia.

    Various metabolic abnormalities, including obesity, insulin resistance, hypertension, dyslipidemia, hyperthyroidism and low vitamin D levels, have been linked to both osteopenia and sarcopenia. Osteosarcopenia is also co…

  • Cpubmed:38531211
    open ↗
    Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

    Glucagon-like peptide-1 (GLP-1), secreted by L cells in the small intestine, assumes a central role in managing type 2 diabetes mellitus (T2DM) and obesity. Its influence on insulin secretion and gastric emptying positio…

  • Cpubmed:33421947
    open ↗
    A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis.

    Fibroblast growth factor 21 (FGF21) has become a promising therapeutic target for metabolic diseases such as type 2 diabetes (T2D), obesity and non-alcoholic steatohepatitis. However, the clinical application of natural …

  • Cpubmed:29915923
    open ↗
    Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) came to market in the year 2005, as a new therapeutic classification, for clinical use in the management of type 2 diabetes mellitus (T2DM). Since 2005, there have be…

  • Cpubmed:36356832
    open ↗
    BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.

    Obesity and its associated comorbidities represent a global health challenge with a need for well-tolerated, effective, and mechanistically diverse pharmaceutical interventions. Oxyntomodulin is a gut peptide that activa…

  • Cpubmed:33969456
    open ↗
    Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.

    The absorption, distribution and elimination of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist for treating type 2 diabetes, was investigated using a population pharmacokinetic model based on d…

  • Cpubmed:30009885
    open ↗
    Battle of GLP-1 delivery technologies.

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong to an important therapeutic class for treatment of type 2 diabetes. Six GLP-1 RAs, each utilizing a unique drug delivery strategy, are now approved by the Food…

  • Cpubmed:31031702
    open ↗
    The Discovery and Development of Liraglutide and Semaglutide.

    The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects on glycemic control and body weight regulation, led to efforts to extend its half-life and make it therapeutically effective in…

Thesis ledger

1 drafts
  • Bconviction 0.79
    qa_pending

    Albumin-hitchhiked GLP-1 analog for once-weekly exposure

    A GLP-1(7-37)-derived peptide engineered with an Aib substitution at position 8, a single C18 diacid acylation on Lys26 via a polar linker, and Lys34->Arg will retain high GLP-1R agonist potency while achieving a terminal half-life of at least 5 days, enabling once-weekly dosing.

Red team

3 critiques
  • Skepticwarning

    The thesis leans heavily on semaglutide as precedent, but the proposed construct is not semaglutide: it uses a GLP-1(7-37)-derived backbone, acylation at Lys26, and Lys34->Arg, whereas semaglutide's clinical PK reflects a specific combined design package, including a different sequence context and linker/acylation geometry. The claim that these 'extended-half-life design principles' will reproduce a >=5 day terminal half-life risks overstating how portable the semaglutide result is across nearby but non-identical analogs.

  • Scientistwarning

    The mechanism description is incomplete and partly overconfident. Aib8 should reduce DPP-4 cleavage, but that alone does not establish global protease stability or receptor potency. Likewise, 'diacid stabilized by cationic albumin residues' is plausible but not demonstrated for this exact linker/headgroup placement, and acylation at Lys26 can materially alter GLP-1R efficacy, bias, and albumin off-rate. The thesis also does not address species-dependent albumin affinity, which can make rodent PK a poor predictor of human half-life, nor does it specify assays to separate slowed absorption, true clearance reduction, and receptor-mediated disposition.

  • Senior Reviewerwarning

    The strongest cited human evidence is a cardiovascular outcomes paper for semaglutide, which validates the therapeutic class but does not directly support the proposed sequence, linker, acylation site, or the quantitative >=5 day terminal half-life threshold. The SAR tractability argument from ChEMBL is also too general to justify this exact design choice. As written, the thesis packages literature-supported principles together with a specific PK claim that is not directly evidenced in the provided corpus.

Dossier preview

11,339 chars · dossier

Dossier · GLP-1 analogs with extended half-life

# Dossier · GLP-1 analogs with extended half-life
**Mission ID**: `msn_0013994f54644073`  
**Target class**: (unspecified)  
**Depth**: standard  
**Started**: 2026-04-30T18:59:36.947+00:00  
**Prediction commit**: `8b690bf75d0982d7001e93f55a91622a25614e7655b8195d5ff76602f66a0b7a`


## Synthesis

> ## Question
Assess w…

Deliverables

  • Buyer-safe dossier (markdown)
    11339 chars
    COMPLETE
  • Synthesis document
    8037 chars
    COMPLETE
  • Thesis records
    1 theses · 19 graded A/B
    REVIEW
  • Red-team critique pack
    3 critiques
    COMPLETE
  • PMID citation map
    12 PubMed references
    INDEXED

Recent runs

  • GLP-1 analogs with extended half-life
    msn_0013994f54644073
    3m 17s
    Today 19:02 UTC